Literature DB >> 26231441

Prevalence of cavum vergae in psychosis and mood spectrum disorders.

Ramón Landin-Romero1, Salvador Sarró1, Paloma Fernández-Corcuera2, Noemí Moro2, Jose Manuel Goikolea3, María Isabel Carrión4, Edith Pomarol-Clotet1, Benedikt L Amann5, Joaquim Radua6.   

Abstract

BACKGROUND: Midline brain abnormalities might increase susceptibility to both first-episode and chronic mental disorder. Evidence of cavum vergae (CV) abnormality in mental disorders is scarce.
METHODS: The presence of CV was assessed by a researcher blind to clinical information in a cross-disorder sample of 639 patients with mood and psychotic disorders and in 223 healthy controls. Homogeneous magnetic resonance imaging methods of acquisition and assessment were applied.
RESULTS: Seven out of 639 patients with mood or psychotic disorders were detected with CV which corresponds to a prevalence of 1.1%. There were no concurrent cases of CV in the healthy control group. Identified cases which are briefly described were diagnosed from bipolar I disorder (n=2), delusional disorder (n=1), brief psychotic disorder (n=1) and schizoaffective disorder (n=3). Patients with CV had descriptively lower current IQ, executive functioning and memory scores in relation to patients without CV but this was not statistically significant. LIMITATIONS: Effects of medication and lack of statistical power of the CV patient group.
CONCLUSIONS: Midline brain abnormalities, such as CV, might represent an unspecific risk factor for the development of severe mental disorders.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cavum vergae; Midline brain; Mood disorders; Psychotic disorders; Septum pellucidum; Structural MRI

Mesh:

Year:  2015        PMID: 26231441     DOI: 10.1016/j.jad.2015.07.020

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  1 in total

1.  Cavum vergae and psychiatric illness: substantive or serendipity?

Authors:  Chandrasekharan Rajasekharan; Vijayakumar Karthik; Muralikrishnan Harikrishnan; Sudhakaran Lekshmi
Journal:  BMJ Case Rep       Date:  2018-06-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.